Author(s): Cole MP, Jones CT, Todd ID
Abstract Share this page
Abstract An introductory clinical trial of the anti-oestrogenic agent IC146474 in late or recurrent carcinoma of the breast is described.Forty-six patients have been treated, of whom 10 have shown a good response. This is of the same order as that seen with oestrogens and androgens.The particular advantage of this drug is the low incidence of troublesome side effects.
This article was published in Br J Cancer
and referenced in Journal of Genetic Syndromes & Gene Therapy